CLL has been the subject of several other research reports. Cenkos Securities Ltd restated a buy rating on shares of Cello Group plc in a research report on Wednesday, September 14th. N+1 Singer restated a buy rating on shares of Cello Group plc in a research report on Wednesday, September 14th. Finally, Peel Hunt restated a buy rating on shares of Cello Group plc in a research report on Wednesday, July 13th. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and an average target price of GBX 123.75 ($1.62).
Shares of Cello Group plc (LON:CLL) opened at 106.55 on Wednesday. The company has a 50 day moving average of GBX 105.65 and a 200 day moving average of GBX 98.83. The stock’s market cap is GBX 92.49 million. Cello Group plc has a 12 month low of GBX 77.10 and a 12 month high of GBX 115.00.
The business also recently disclosed a dividend, which will be paid on Friday, November 4th. Shareholders of record on Thursday, October 6th will be given a GBX 1 ($0.01) dividend. This represents a yield of 0.94%. The ex-dividend date of this dividend is Thursday, October 6th.
Cello Group plc Company Profile
Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.
Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with MarketBeat.com's FREE daily email newsletter.